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ABSTRACT  
Sustained release and prevention of burst release for low half-life drugs like Diclofenac sodium is 
crucial to prevent drug related toxicity. Electrospun nanofibers have emerged recently as potential 
carrier materials for controlled and sustained drug release. Here, we present a facile method to 
prevent burst release by tuning the surface wettability through template assisted micropatterning 
of drug loaded electrospun cellulose acetate (CA) nanofibers. A known amount of drug 
(Diclofenac sodium) was first mixed with CA and then electrospun in the form of a nanofabric. 
This as-spun network was hydrophilic in nature. However, when electrospinning was carried out 
through non-conducting templates, viz nylon mesh with 50 and 100μm size openings, two kinds 
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of   hydrophobic micro-patterned CA nanofabrics were produced. In vitro transdermal testing of 
our nanofibrous mats was carried out; these tests were able to show that it would be possible to 
create a patch for transdermal drug release. Further our results show that with optimized micro-
patterned dimensions, a zero order sustained drug release of up to 12 h may be achieved for the 
transdermal system when compared to non-patterned samples. This patterning caused a change in 
the surface wettability, to a hydrophobic surface, resulting in a controlled diffusion of the 
hydrophilic drug. Patterning assisted in controlling the initial burst release, which is a significant 
finding especially for low half-life drugs. 
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Introduction 
Novel drug delivery systems are designed to deliver the bioactive agents in a controlled manner to 
attain therapeutic doses at a target site. The aim is to do this with minimal systemic side effects 
associated with the burst release and high frequency dosage for drugs that have low 
bioavailability.1 Diclofenac sodium (a salt of 2-(2,6-dichloranilino) phenylacetic acid) is one such 
drug with a short biological half-life (of 1-2 hours) that undergoes rapid hepatic first pass 
metabolism following oral administration.2 Frequent dosing is needed to maintain the therapeutic 
levels, and fluctuations in the drug plasma levels have adverse effects on gastric mucosa causing 
peptic ulcers and bleeding.3 Diclofenac sodium (DCF) is an extensively used nonsteroidal anti-
inflammatory agent for the treatment of arthritis, musculoskeletal disorders, toothache, and 
dysmenorrhea, as well as in catheter, heart valve linings for symptomatic relief of post-operative 
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pain and inflammation.4 Transdermal patches delivering DCF for local pain management would 
be very useful for treating local pain. Transdermal patches based on polymeric micro/nano carrier 
formulations pose alternatives to conventional systems. These can sustain the release, maintain 
constant plasma drug levels at the target site and reduce dosing frequency leading to improved 
patient compliance and reduced adverse effects.5  
The mechanism of drug release from polymeric mico/nano carrier systems is either diffusion or 
degradation controlled depending on the nature of the polymeric system. Drug release from 
polymeric systems can be controlled by varying the surface wettability of the drug carrier.6 For 
hydrophilic drugs such as Diclofenac sodium, the surface of the carrier system should be 
hydrophobic to prevent a burst release.6-8 The surface of a drug carrier system can be made 
hydrophobic by using a low surface energy coating9 and micro/nano-patterning using techniques 
such as photolithography10 and chemical vapour deposition11. Nevertheless, these methods often 
involve complex procedures to introduce functional groups and patterns and at the same time they 
pose issues in chemical integrity.12  
Tuning the surface wettability through electrospinning has gained attention in recent times. 
Electrospinning is a facile yet effective technique which offers the benefit of fabricating polymeric 
nanofibers with unique micro/nano scaled topologies, which can alter surface wettability.13 
Nanofibers with patterned surfaces can be fabricated by modifying the electric field14-15, by self-
assembly16 and by using a patterned collector.17-19 Patterned surfaces fabricated by using collectors 
reported so far have used conductive templates. However, the preparation of conductive patterned 
surfaces requires expensive processing such as lithography. 
In the current study, a non-conductive nylon mesh was used as a collector. The deposition 
mechanism is different for conducting and non-conducting collectors. The technique reported in 
4 
 
this paper is scalable due to the availability of nylon meshes with different spacings.  
Recently our group has shown that the wettability of electrospun fabrics can be tuned by simply 
using a dielectric mesh over the collector with different opening sizes.20 We have electrospun 
cellulose acetate (CA) using a nylon mesh template with three different mesh sizes (50, 100 and 
200μm) to obtain a one-sided patterned surface with different wettability (a hydrophilic to 
hydrophobic transition). Nanofabrics collected on 50 and 100μm spacing nylon meshes showed a 
clear transformation to a hydrophobic behavior. Spacing greater than 200 μm essentially behaves 
same as non-patterned samples and exhibit hydrophilic behavior, so to control the release of the 
drug, 50 and 100μm mesh spacings have been chosen to tune wettability in the hydrophobic region. 
CA is a hydrophilic, biocompatible polymer, whose nanofibers have been extensively studied in 
drug delivery applications.21 The current study aims to demonstrate the ability of micropatterned 
CA nanofibers to control burst release and maintain a zero order profile in comparison to non-
patterned nanofibrous mats and spin coated non-fibrous thin films. Micropatterning of nanofibers 
allows us to control the porosity that affects the diffusion of buffer into the matrix thereby 
influencing drug release. For clearly demonstrating this, a comparison was made using thin films. 
Spin coating which is one of the most facile way to produce thin films has been chosen for this. 
The ability to do this is important because it would allow the production of a fibrous construct that 
could be used as part of a drug delivery patch. 
 
 
 
 
Materials and methods  
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Materials 
CA (MW = 29000) and Diclofenac sodium salt were purchased from Sigma Aldrich, UK. N,N-
dimethylacetamide (DMAc) and acetone were purchased from Merck Specialties Private Limited, 
India. Nylon meshes with opening sizes of 50 and 100 μm respectively were purchased from 
Plastok, UK. Ultipor nylon 6,6 membrane with a pore opening of 0.3 µm was purchased from Pall 
India Private Ltd. Potassium chloride was purchased from HIMEDIA, while Di-sodium hydrogen 
orthophosphate dehydrate (analytical grade) was purchased from SDFCL, Mumbai. Potassium 
dihydrogen ortho-phosphate, sodium carbonate anhydrous and sodium chloride were purchased 
from Sisco Research Laboratories, Mumbai. 
 
Sample Preparation 
50 mg of Diclofenac sodium salt (DCF) was dissolved in 10 ml of mixed solvent comprising 
acetone and DMAc in a 2:1 (v/v) ratio. CA was slowly added and stirred for 3 h to obtain a ~13 % 
w/v homogenous solution. This solution was then used to make drug loaded thin films (CA-
DCFThin film), non-patterned electrospun nanofiber mats (CA-DCFNP), patterned nanofibers 
deposited on nylon meshes with 50µm spacings (CA-DCFP-50m),  and 100µm spacings (CA-DCFP-
100m). The weight percentage of DCF with respect to CA in the nanofibers and thin films was 3 % 
(w/w).  
A thin film of CA-DCF was prepared on a polymethyl methacrylate substrate for further for drug 
release studies. The polymer solution was deposited on the substrate prior to spinning it at 1600 
rpm for 20 s to obtain a thin film of a similar thickness to the nanofiber mat at room temperature. 
Thickness of all the samples was measured using Vernier calipers. The spin coater used was mode: 
spin NXG-P1 from Apex Instruments (India).  
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 CA-DCF solution was electrospun using equipment purchased from E-Spin Nanotech Pvt. Ltd, 
India. The solution was pumped out at a fixed flow rate of 10 µl/min through an 18 gauge blunt 
needle. The electric field was maintained at 1 kV/cm over a 10 cm spacing between the syringe 
and the collector plate. Three types of fibrous mats were obtained by depositing the nanofibers on 
nylon meshes with opening sizes of 50 and 100 µm and lastly directly onto an aluminum foil 
collector with no mesh; these samples were labelled CA-DCFP-50m, CA-DCFP-100m and CA-DCFNP, 
respectively. Another CA solution without DCF was used to make nanofibers and thin films. For 
the preparation of nanofibers and thin films without drug, 16 % (W/V) of cellulose acetate was 
dissolved in a mixed solvent system containing acetone and DMAc in 2:1 proportion. The 
electrospinning parameters were same as mentioned above and the patterned (CA-p50 and  CA-
p100)  and non-patterned fibers were prepared by depositing fibers over nylon mesh with 50 µm 
and 100 µm mesh and aluminum foil respectively. Thin films without drugs were casted in similar 
fashion as mention above. Thin films and non-patterned nanofibers without the presence of the 
drug were named CAThin film and CANP respectively. Patterned nanofibrous mats without the 
presence of the drug produced with either a 50mesh or 100mesh were named as CAP-50m and CAP-
100m respectively. Thickness of all these samples (without drug) as measured by Vernier caliper 
was same as for the samples with drug. 
Further experimental details along with a schematic are provided in Supplementary Information 
(Figure S1).20  
 
 
Characterization 
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The surface morphologies of electrospun fibers were assessed using a Desktop Scanning Electron 
Microscopy (SEM) (Model: Pro X, Phenom, Netherlands) at a 5 kV voltage, with a working 
distance of 10 mm. Average fiber diameter was calculated from SEM images using Image J 
software considering 50 fibers into consideration for each images. For a given sample, at least two 
SEM images were considered for more precise measurement of average fiber diameter. 
Electrospun CA-DCF fibers, CA nanofibrous mats and DCF powder were characterized using a 
Fourier Transform Infrared (FTIR) spectrometer (Model: Alpha-P, Bruker Corporation, USA) 
working in an attenuated total reflection (ATR) mode in the wavenumber range of 4000 and 500 
cm−1. The wettability of the all nanofiber as well as thin film samples with and without drug were 
studied in triplicate using a sessile drop method with a goniometer (Rame-Hart, USA; Model: 290-
F4). A 3 μl deionized (DI) water droplet, ~2 mm in diameter, was used for contact angle 
measurements. The surface area of the nanofibers and thin films were calculated using multi-point 
Brunauer-Emmett-Teller (BET) analysis. N2 physisorption was determined using a Micromeritics 
ASAP 2020 physisorption analyzer (USA). All samples of 100 mg mass were degassed at 80 °C 
for 1-2 h in a nitrogen atmosphere. The BET and porosity results are presented in Supplementary 
Information (Table 1S). XRD patterns were obtained using a Bruker X-ray diffractometer with 
nickel-filtered Cu Kα radiation, a 2 step size of 0.02°◦ from 5 to 60°,  and a dwell time of 3s. 
DSC analysis of all samples was carried out using a simultaneous thermal analyzer NETZSCH 
STA 449 F3 Jupiter instrument. Samples were weighed directly on aluminium pans and scanned 
between 30-300 °C at a heating rate of 10°C/min in an Argon atmosphere at a 50ml/min flow rate. 
Further, we measured the drug entrapment efficiency in drug load nanofibers (patterned and non-
patterned) and thin film samples. Drug entrapment efficiency is defined as the weight ratio of 
amount of drug loaded in the nanofiber to the total amount of drug added in the feed solution. To 
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determine the entrapment efficiency of drug loaded nanofibers and thin film, the samples of 
predetermined mass were sonicated in 20 mL of phosphate buffered saline (PBS) pH~5.5 for 15 
minutes, with pulse duration of 2 seconds-“On” and 3 seconds “Off”. The release medium was 
then centrifuged for 5 minutes at 2000g to bring down the nanofiber and thin film fragments. The 
total amount of drug released in PBS was estimated by UV-Vis analysis of the resultant release 
medium and then correlating the absorbance values with standard plot of Diclofenac sodium.  
Drug entrapment efficiency was calculated by following equation: 
Entrapment efficiency = (Total mass of drug released from nanofiber/Mass of total drug added) 
×100                                                                                                                                               (1) 
 
In vitro transdermal drug release study 
A modified Franz diffusion cell was used for the transdermal drug release studies. It consisted of 
an upper donor chamber and a lower receiver chamber. In between these two chambers, a 
multipore membrane of ~0.3 μm pore size was placed (which mimics the porosity of skin) followed 
by a test sample with the patterned side facing towards the donor chamber. PBS of pH~5.5 was 
used for the release studies to match the pH of skin.  The donor chamber was filled with 20ml of 
PBS pH ~ 5.5 buffer and the entire set up was kept at 37 ± 1 °C with a 50 rpm rotation. 3 ml 
aliquots were collected at specified time intervals for measurements and replaced with the fresh 
buffer to maintain sink conditions. All the experiments were conducted in triplicate. The amount 
of drug released was estimated from the UV absorbance (SATHYAM LI-2700 double beam UV-
Visible spectrophotometer) of the removed aliquots and a predetermined calibration curve.  A 
schematic of the transdermal release study is presented in Figure S2 (Supplementary information). 
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A calibration curve of DCF in PBS 5.5 was determined and the R2 value was found to be 0.99 
(Figure.7). 
 
Results and Discussion 
Surface morphology and wettability 
Figure. 1 reports typical SEM and contact angle (with buffer PBS pH~5.5) images of drug loaded 
non-patterned and micro-patterned CA nanofibers mats. Figure 2 reports typical SEM and contact 
angle (with buffer PBS pH~5.5) images of non-patterned and micro-patterned CA nanofibers mats 
without the presence of the drug. From SEM analysis we could observe the uniformly distributed 
fiber mat with smooth, slender and beadless nanofibers in all the samples. The SEM analysis of 
non-patterned samples showed random and uniform deposition of nanofibers while in case of 
patterned nanofibers we could vividly observe the patterns showing the deposition along the 
meshlines. Random deposition of fibers as observed for CA-DCFNP (Fig. 1a) exhibits a water 
contact angle of 33.9±0.5° (hydrophilic). During template-assisted electrospinning, initially for 
about 10 min, nanofibers deposit over the nylon threads in the mesh. However, later on in the 
process the fibers deposit randomly due to a decay in the dielectric mesh effect.20 This preferential 
deposition over the mesh lines followed by a random deposition results in micro-patterned 
nanofibrous mats with two surfaces with different wettability. After peeling (Figure S1), the 
surface towards the nylon mesh exhibits hydrophobic properties (Figures 1b and 1c) with contact 
angles of 134.6±0.1° and 117.6±0.1° for CA-DCFP-50m and CA-DCFP-100m, respectively. The 
surface facing the syringe exhibits hydrophilic properties, similar to CA-DCFNP. The patterned 
samples, CA-DCFP-50m and CA-DCFP-100m, exhibit cup-like non-continuous air traps which 
suspend the water droplet, leading to an increase in the hydrophobic behavior. For CA Nanofibers 
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without drug, contact angle for CANP was found to be 29.7±0.1°. The surface towards the nylon 
mesh, after being peeled, exhibits hydrophobic behaviour (Figure. 2) with contact angles of 
129.8±0.1⁰ and 137.8±0.1⁰ for CAP-100m and CAP-50m, respectively. The surface towards the syringe 
exhibits hydrophilic behaviour, similar to CANP (29.7±0.1°). The contact angle values for CAThin 
film and CA-DCFThin film, were found to be 73.2±0.2° and 71.0±0.1°, respectively (Figure.3.) These 
are indicative of intermediate hydrophilic-hydrophobic properties. The effect of micro-patterning 
on electrospun nanofibers in terms of how it effects the water contact angle is explained in our 
recent work.20 In summary, we have demonstrated the fabrication of micropatterned nanofiber 
mats with tunable wettability using template based electrospinning. Patterned nanofiber mats were 
shown to possess hydrophobic behavior due to a non-wetting capillary pressure which in turn is 
due to air trapped in the non-communicating air gaps. Briefly, for micropatterned samples capillary 
pressure plays an important role in surface wettability. Air trapped in cup type structures in 
micropatterned mats possess a non-wetting capillary pressure. This non-wetting pressure increases 
with decreasing spacing between features and results in a higher contact angle for CA-DCFP-50 and 
CAP-50 when compared to CA-DCFP-100 and CAP-100.  
Here, in this study we have used patterned nanofiber mats as drug carriers and investigated the 
effect of wettability of mats on drug release. Average fiber diameters as calculated from SEM 
images using Image J software are listed in Table 1. Drug entrapment efficiency was calculated by 
following equation and the results are given in Table 1. 
 
Entrapment efficiency = (Total mass of drug released from nanofiber/Mass of total drug added) 
×100                                                                                                                                              (1) 
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Figure.1. SEM and contact angle (with PBS pH ~5.5) images for (a) & (a’) CA-DCFNP , (b) & (b’) 
CA-DCFP-50m and (c) & (c’) CA-DCFP-100m 
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Figure.2.  SEM and contact angle images of (a) & (a’) CANP , (b) & (b’) CAP-50m and (c) & (c’) 
CAP-100m 
 
 
Figure.3. Contact angle images of (a) CAThin film, (b) CA-DCFThin film 
 
Table.1 Average fiber diameter and drug entrapment efficiency  
Sample Average fiber diameter (nm) Drug entrapment efficiency 
(%) 
CANP 361±90 - 
CAP-50m 362±91 - 
CAP-100m 368±84 - 
CA-DCFNP 351±98 97±0.74 
CA-DCFP-50m 349±95 99±1.74 
CA-DCFP-100m 
CA-DCFThin film           
349±95 
- 
98±1.23 
56±1.85 
 
FTIR Analysis 
FTIR analysis was performed for CANP, DCF powder and CA-DCFNP in order to understand the 
drug polymer interaction. FTIR result confirms the successful incorporation of DCF in CA 
nanofibers without any chemical interactions (Figure 4). 
The IR spectra of CANP (Figure 4a) have acetate group vibrations located at ~599 cm
-1 (O-C-O bend 
of ester)   ~895 cm-1 (δCH2),   ~1047 cm-1 (υ C-O-C) , ~1236 cm-1 (υ C-O-C),  ~1373 cm-1 (υC-CH3) , 1624 
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cm-1  (alkenyl υC=C stretching) ~1754 cm-1  (υ CO ), ~2949 cm-1  (υC-CH3) and  ~3477 (υ OH) 24. The 
IR spectrum of DCF powder (Figure 4b) has a characteristic  vibration located around ~746-778 
cm-1 due to the substituted phenyl group stretch, υ C=C vibrations from 1400 to 1570 cm-1, aromatic 
=CH stretch at 2962-3079 cm-1, phenolic stretch at 3254 cm-1, characteristic primary amine stretch 
at 3390 cm-1 along with a small peak for υ C-Cl located at ~558 cm-1 22-23. The IR spectra of DCF 
loaded CA nanofibers (as shown in Figure 4c) has shown all the characteristic peaks from CA. For 
instance, we could observe same peaks at 599 cm-1, 895 cm-1  1047 cm-1,1236 cm-1, and 1754 cm-
1 while peak shifts to higher wavenumber means lowering of bond length were recorded at 1377 
cm-1  and 1632 cm-1 corresponding to that at 1624 cm-1 and 1373 cm-1. The successful 
incorporation of drug is prominently shown through aromatic C-H bending at 786 cm-1, amide 
C=O stretch at 1632 cm-1, and incorporation of primary amines at 3500 cm-1 which suggests the 
existence of hydrogen bonding between the drug and the CA fibers. No new peaks and no 
significant shift in the peak position were observed for the CA-DCFNP samples, when compared 
to pristine DCF and CANP. This further shows the stability of the drug while loaded in CA 
nanofibers. Further, as the chemical composition including the drug loading, solution 
concentration and parameters for electrospinning and spin coating were the same for both patterned 
nanofibers (CA-DCF-p50 and CA-DCF-p100) and CA-DCF Thin film, no separate spectra was 
recorded for these samples. 
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Figure. 4. Typical FTIR spectra for (a) CANP, (b) DCF powder and (c) CA-DCFNP 
 
DSC Analysis 
The determination of the physical state of the drug in the nanofibers is essential to achieve the 
desired drug release profiles. In the present study, DSC and XRD analysis was undertaken to 
determine the physical status of the components of the composite nanofibers. 
DSC analysis was performed for DCF powder, CANP, drug loaded CA nanofibers (CA-DCFNP, 
CA-DCFP-50m, CA-DCFP-100m) and the drug loaded thin film (CA-DCFThin film) samples. An overlay 
of the DSC thermograms is presented in Figure.5. The thermogram for CANP shows a broad 
endothermic event located at around 60-100°C which is attributed to the dehydration of the 
polymer. A broad low endothermic is observed around 215-230 °C, which is attributed to the 
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melting (Tm) temperature. Absence of clear melting endothermic peak in thermogram of CA 
indicates the amorphous nature of CANP. 
 The DSC thermogram of pure DCF exhibited a transition peak at 54°C as a result of some 
structural rearrangements (polymorphic transformations). A sharp peak at 274°C corresponds to 
the melting temperature of DCF, which suggests that DCF is crystalline in nature. Peaks around 
300°C may be attributed to the initiation of oxidative degradation of the drug. 
The thermograms of CA-DCFThin film, CA-DCFNP, CA-DCFP-50m and CA-DCFP-100m shows a broad 
endothermic event located at around 60-100°C which is attributed to the dehydration of the 
polymer. They also exhibited a weak and broad transition ranging from 215 to 230 °C due to the 
melting temperature (Tm) of CA, suggesting that CA nanofibers and thin film samples retained 
amorphous nature even after drug loading. The CA-DCFThin film, CA-DCFNP, CA-DCFP-50m and 
CA-DCFP-100m samples did not show any sharp melting peak as in case of pure DCF, suggesting 
that the DCF present in the composite nanofibers was in an amorphous state, having lost its original 
crystalline state. As patterning does not alter the melting point of DCF loaded CA nanofibers, 
similar results were observed for the entire drug loaded nanofibers.  
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Figure.5. Typical DSC thermograms of CANP, DCF powder, drug loaded CA nanofibers (CA-
DCFNP, CA-DCFP-50m, CA-DCFP-100m) and thin film (CA-DCFThin film) samples. 
 
XRD Analysis 
The presence of numerous distinct peaks in the XRD patterns of pure DCF powder indicates that 
DCF is a crystalline material with characteristic diffraction peaks (Figure 6a). CANP did not exhibit 
any distinct sharp peaks and a broad ‘hump’ was observed in the XRD pattern (Figure 6b), 
indicating the amorphous nature of CA. Irrespective of patterning, there are no peaks pertaining to 
crystalline DCF are detectable in the XRD patterns of all the three DCF-loaded CA nanofibers 
(Figure 6c-e), indicating that the entire DCF loaded in the CA nanofibers no longer retained its 
crystalline nature, but had been totally transformed into an amorphous state. 
 
The thin film sample (CA-DCFThin film) also exhibits a characteristic ‘hump’ attributed to an 
amorphous state to the material (Figure. 6f). 
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The XRD results are in agreement with the findings from DSC, likewise validating that DCF 
molecules were well distributed in the CA nanofiber matrix and were present in a complex manner 
in which the original structure of the pure, crystalline DCF material was lost.  
 
Figure 6.  Typical XRD patterns of (a) DCF, (b) CANP, (c) CA-DCFNP, (d) CA-DCFP-50m, (e) CA- 
DCFP-100m, (f) CA-DCFThin film samples. 
 
In-vitro transdermal drug release 
A calibration curve of DCF in PBS pH~5.5 is presented in figure.7.  In vitro transdermal release 
profiles of all the samples are presented in Figure 8. The cumulative percentage drug releases after 
48 h for CA-DCFP-50m, CA-DCFP-100m, and CA-DCFNP were found to be 99.5, 98.6 and 97.8, 
respectively (Figure 8a). Only 32.5% of the drug was released in the case of CA-DCF Thin film by 
the end of 48h due to the low porosity and the poor penetration of the buffer solution into the 
material. As summarized in Table 1S, the porosities of CA-DCFP-50m and CA-DCFP-100m were 
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found to be close to 0.986 and 0.982, while for CA-DCFNP and CA-DCF Thin film, values of 0.925 
and 0.356 were obtained respectively.  
The cumulative percentage drug releases after first 12h for CA-DCFP-50m, CA-DCFP-100m, and CA-
DCFNP were found to be 52.7, 72.6 and 76.5, respectively (Figure. 8b). Only 14.5% of the drug 
was released in case of CA-DCF Thin film by the end of 12h due to the low porosity and the poor 
penetration of the buffer solution into the material. Burst release was observed in CA-DCFNP; 
whereas a gradual incremental profile was observed with 100M. A completely linear profile was 
observed for the CA-DCFP-50m sample; <15% release was observed in CA-DCF Thin film. A zero 
order release profile (where amount of drug release at each time point is same) was observed after 
12h for the CA-DCFP-50m sample, 3h for the CA-DCFP-100m sample, and 1h for the CA-DCFNP 
sample. 
It is evident from the above result that drug release in transdermal patches depends upon the surface 
wettability.17 When the contact angle of the surface in touch with the buffer is small (hydrophilic) 
there is an enhanced wetting, thereby increasing the extent of matrix diffusion and swelling. This 
assists in an increased release of the drug. In this case, patterning induced hydrophobicity results 
in increased contact angles of 134.6±0.1° and 117.6±0.1° for CA-DCFP-50m and CA-DCFP-100m 
respectively when compared to CA-DCFNP (33.9±0.5°). Due to the formation of air pockets at the 
interface of the patterned surface and the release medium, the effective area in contact with the 
medium is reduced, thus preventing burst release. In CA-DCFThin film, even though the effective 
surface area in contact with the medium may be high, a lower porosity causes poor penetration of 
the buffer, and therefore the total cumulative release is reduced. There is a significant difference 
in the amount of drug released was observed with CA-DCFP-50m for CA-DCFP-100m. Even though 
both are patterned nanfibrous mats, CA-DCFP-100m was unable to sustain zero order release for 
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much longer time when compared to CA-DCFP-50m. This may be due to the formation and retention 
of air pockets at the interface of CA-DCFP-50m and the buffer. The CA-DCFP-100m sample was 
however unable to retain air pockets for long durations as its contact angle is lower than CA-DCFP-
50m.  When the nanofibrous mat becomes more wetted by the buffer solution, the surface area of the 
mat in contact with the buffer increases. The drug  then diffuses into the buffer more rapidly  due 
to its hydrophilicity. Comparing the CA-DCFP-50m and CA-DCFP-100m samples, the latter has a 
lower contact angle with the buffer, and a greater surface area in contact with the buffer. Therefore, 
the amount of drug released is expected to be more than for CA-DCFP-50m. 
After 24 h, the release profiles of all the three (CA-DCFNP, CA-DCFP-50m and CA-DCFP-100m) 
samples were found to be similar. As time progresses, the trapped air is released and the interface 
becomes completely wetted out. This leads to the diminishing of any surface effects on drug release 
translating to similar release profiles for patterned as well as non-patterned samples after 24 h.8, 25 
 
Figure.7. Calibration curve of DCF in PBS pH~5.5 
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Figure.8. Cumulative in vitro transdermal release profiles of DCF from (CA-DCFNP , CA-DCFP-
50m , CA-DCFP-100m, and CA-DCF Thin film,) in PBS pH~5.5 for (a) 48h (b) first 12h  
 
After an initial phase of drug release from the surface, the drug tends to release from the bulk, 
where porosity plays an important role in the process. The swelling of the mat and the diffusion of 
the drug from the polymeric matrix increases with an increase in porosity. As CA-DCFP-50m has 
the highest porosity amongst the three samples, slightly higher cumulative release is observed after 
24h. However, given enough time, all samples exhibit a similar cumulative release.  
Mathematical modeling of release kinetics 
Well-established mathematical models are available in the literature to understand and infer drug 
release mechanisms. The drug release profile data were fitted with various existing mathematical 
models in order to better understand the drug release mechanisms. These models were zero order, 
first order, Higuchi, Hixson-Crowell and Korsmeyer-Peppas.  
In the transdermal release studies, a zero order profile was observed for first 12, 3 and 1 h of release 
with CA-DCFP-50m, CA-DCFP-100m and CA-DCFNP samples respectively as seen in Figure 9. (R
2 
values obtained from the regressions are included in Table.2). This implies that the drug release 
rate is constant and independent of concentration in these regions. Slope of the linear fitted curves 
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gives information on the drug release rate. Slopes of CA-DCFNP, CA-DCFP-50m and CA-DCFP-100m 
were found to be 32.3, 4.5 and 11.7 % h-1, respectively; the release rate is therefore highest for 
CA-DCFNP amongst the three samples.  
The rate-limiting step for water soluble drug (DCF) loaded in water insoluble and non-erodible 
polymeric systems (CA Nanofibers) is the diffusion through typically a water-insoluble barrier. 
DCF loaded CA Nanofibers is matrix-based system, where the drug is uniformly distributed in the 
polymeric matrix and water permeation leads to swelling of the matrix causing pores. In order for 
effective diffusion of drug molecules to occur, the pore size of the swelled matrix must greatly 
exceed the size of the hydrophilic drug molecule. Extent of wetting of the nanofibrous mat at 
interface with buffer determines the degree of diffusion of buffer and swelling of matrix. In case 
of CA-DCFP-50m, air trapped at the interface reduced the extent of wetting and diffusion of buffer, 
thereby reducing the burst release of drug at initial phase. Therefore, zero order profile was 
observed for 12h in case of CA-DCFP-50m. Due to the absence of such mechanism in rest of the 
samples, zero order profile was short-lived.  
After this zero order profile behavior, CA-DCFP-50m followed a Hixson-Crowell model till 48h. 
According to Hixson-Crowell model, a plot of cube root of the unreleased fraction of the drug 
versus time will be linear if the equilibrium conditions are not reached and if the geometrical shape 
of the pharmaceutical dosage form diminishes proportionally over time.  
As described earlier, after first 12h, release rate was increased in case of CA-DCFP-50m when 
compared to CA-DCFNP and CA-DCFP-100m pertaining to highest porosity of the matrix which 
assisted in enhanced penetration of buffer.  As buffer penetrates and swelling takes place, a 
transformation of polymer from a glassy to rubbery state occurs and the dimension of the matrix 
increases slightly. This transformation of state essentially creates a gel layer of rubbery region for 
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the drug to diffuse, in which the drug diffusivity increases significantly. As a result, during the 
swelling, two different states, namely the glassy core and rubbery surface (gel layer), exist in the 
polymer matrix. At this point, two moving fronts exist, namely the glassy-rubbery front (R) and 
the rubbery–solvent front (S). Initially during swelling, front R moves inwards, whereas front S 
moves outward. As soon as the polymer at interface S achieve thermodynamic equilibrium with 
the surrounding medium, drug at interface S dissolves and create pores and, thus, front S moves 
inwards.  Both fronts move inwards till the front R diminishes as the glassy core wanes. Later, 
only the rubbery region exists and drug dissolution at interface S eventually controls the shrinking 
process. This indicates that the drug release rate in CA-DCFP-50m is limited by the drug particles 
dissolution rate and not by the diffusion that occurs through the polymeric matrix. This model has 
been used to describe the role of surface volume relationships on release profile keeping in mind 
the diminishing surface of the drug particles during the dissolution26, 27. 
After zero order profile, CA-DCFNP and CA-DCFP-100m exhibited first order release kinetics till 
48h, which is matrix diffusion controlled and concentration gradient dependent. Drug release rate 
was higher for CA-DCFNP and CA-DCFP-100m when compared to CA-DCFP-50m during first 12h, 
but, decreased later.  About 75% of drug release was observed within first 12h for CA-DCFNP and 
CA-DCFP-100m, less amount of drug was available in matrix for further release.  As per first order 
fitting, drug release rate is proportional to the amount of drug remaining to release from the 
nanofibrous mat26, 27. Therefore, release rate was decreased after 12h.   
As the rate of diffusion depends on the surface wettability and therefore is due to differences in 
contact angles. The three samples show very different release profiles. In the first order phase, 
drug releases from the bulk of the porous matrix, where concentration gradient and distance of 
matrix to fresh buffer affects the release.  
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The two main advantages of the CA-DCFP-50m patterned mats are – control over burst release, and 
the presence of a zero order profile up to 12h. As discussed earlier, this kind of a patterned release 
system could be useful for low half-life drugs. The patterning would prevent burst release and 
extend the release period for these materials.  
Release study of electrospun nanofibers loaded with Diclofenac sodium was extensively studied 
by complete immersion test26-31 including transdermal release as well. However in these studies, 
up to 50% of drug release was observed in complete immersion test and >25% of the drug release 
was observed in transdermal first 2h28-33. There was minimal or no control over burst release.  None 
of these studies achieved 12h zero order release profile with a controlled release profile till 48h28-
33. In the present study, non-patterned electrospun fibers were unable to achieve longer zero order 
profile much similar to that of earlier studies. However altering the surface wettability of 
electrospun nanofibers through template based micropatterning played pivotal role in achieving 
zero order profile. Even though CA-DCFP-100m is patterned, it was unable to achieve prolonged 
zero order profile. Hence, close control of the mesh spacing is crucial to obtain desired results.  
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Figure.9. Zero order fitting curves for CA-DCFNP (first 1h), CA-DCFP-100m (first 3h), CA-DCFP-
50m (first 12h) samples. 
 
Table.2 Zero order release region for transdermal study 
Sample Time point till which 
release followed zero 
order (h) 
R2 value for zero 
order fitting 
Slope 
(% h-1) 
CA-DCFNP First 1h 0.997 32.3 
CA-DCFP-50m First 12h 0.977 4.5 
CA-DCFP-100m First 3h 0.998 11.7 
 
Conclusions 
The effect of a variation in surface wettability of drug embedded nanofibrous and patterned 
polymeric matrix on the transdermal release of a hydrophilic drug (Diclofenac sodium) has been 
successfully investigated. The variation in wettability was obtained by tuning the air-liquid 
interface of a patterned mat, by changing the template mesh dimensions used in an electrospinning 
process. A much higher drug release was obtained for nanofibrous mats (patterned and non-
patterned) compared to a thin film of the same thickness obtained by spin coating. This was thought 
to be due to an increased solid-liquid interface. The patterned side of the networks showed 
controlled release due to a minimized solid-liquid interface compared to a non-patterned 
electrospun mat.Patterned mats obtained using 50 µm mesh demonstrated zero order release up to 
12 h, as compared to 3 h and 1 h for a 100 µm mesh and a non-patterned mat respectively. This is 
due to higher contact angle for the 50 μm mesh sample, which reduces the contact area and hence 
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controls the release. This suggests further fabrication of multi-layered hydrophobic mats would be 
required to obtain a zero order profile for an extended period of time. 
Further, several other high potent drugs with low half-life could be loaded in micro-patterned 
nanofibrous mats to achieve zero order profile for transdermal applications. Multiple layers of 
micropatterned nanofibrous mats could be stacked together to control the drug release from the 
surface as well as from the bulk. Such multilayer patterning could control the burst release in 
implantable systems and depot formulations as well. By this way, they may provide a zero order 
profile for prolonged time, even after 12h. 
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